Epitalon
Epithalon / AEDG (Ala-Glu-Asp-Gly)
Epitalon (Epithalon) is the flagship of the longevity-peptide world — a tiny pineal-gland peptide from Russian gerontologist Vladimir Khavinson's research, studied for telomerase activation, melatonin/sleep and anti-aging. It's dosed in a distinctive way (short intensive courses, a few times a year). This guide covers how Epitalon works, what the research honestly shows, dosing, safety and status.
Epitalon quick facts
| Reported research dosing | 2mg-5mg |
| Route | Subq |
| Cycle length | 10-20 Days |
| Frequency | 1x Daily PM |
| Half-life | Short (pineal accumulation) |
| Forms | Injectable, Nasal, Oral |
| Evidence level | Russian human studies + animal |
Short courses, 1–2x a year — that's the studied pattern. Don't run it year-round.
How Epitalon works
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on epithalamin, a natural extract of the pineal gland. Its two most-cited mechanisms: first, telomerase activation — in cultured human cells it's reported to switch on the telomerase enzyme and lengthen telomeres (the protective caps on chromosomes that shorten with age). Second, it supports pineal function and melatonin production, which matters because the aging pineal calcifies and melatonin declines, disrupting sleep and circadian rhythm.
What the research honestly shows
This is where honesty matters. Animal studies (fruit flies, rats, tumor-prone mice) report increased average and maximum lifespan — striking results. But much of that evidence comes from Khavinson's own research group with limited independent replication, and in humans the data is limited to telomere-length measurements and longevity observations in his patients. There are no randomized controlled trials of Epitalon for human lifespan. So: mechanistically fascinating and promising, but genuinely unproven for the big anti-aging claims.
Epitalon dosing (research reference)
Epitalon has a signature dosing pattern unlike most peptides. Khavinson's protocol references 5–10 mg per day by injection for 10–20 consecutive days — that's one 'course' — repeated only 2–3 times per year rather than daily year-round. It's supplied as a lyophilized powder, reconstituted with bacteriostatic water; the calculator above converts a research amount into syringe units. This summarizes existing references for education only, not dosing advice.
Safety & side effects
Epitalon is generally reported as well tolerated in the available research, with few acute side effects noted — consistent with the small-peptide, short-course profile. That said, the long-term human safety picture is thin, and its telomerase-activating mechanism is an area researchers watch (telomerase activity is a double-edged concept in cell biology). Research-market purity varies. Educational only, not medical advice.
Related compounds
Epitalon is the best-known of the Khavinson bioregulators — a family of short peptides (Vilon, Thymalin and others) proposed to normalize tissue-specific gene expression. It's frequently the centerpiece of longevity protocols and pairs conceptually with NAD+ and other aging-focused tools.
Legal & regulatory status
Epitalon is not FDA-approved and is sold as a research compound (research use only). It has been studied and used in Russia. Follow the laws that apply to you.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients, real endpoints, published in Russian, and largely without the blinding, randomisation or independent replication a Western regulator would require. That is genuinely more than nothing and genuinely less than a trial, and the honest read sits between the two.
📊 Correlative data
- The Khavinson group published multi-year follow-up in elderly Russian cohorts reporting reduced mortality and normalised melatonin rhythm. These are the strongest human claims made for any bioregulator and the hardest to verify — largely single-group, rarely blinded, and never independently replicated outside Russia.
- Modern use is short annual courses, which is the protocol those studies used rather than something invented later.
🧪 Theoretical / extrapolated
- A tetrapeptide (Ala-Glu-Asp-Gly) proposed to act on the pineal gland and to induce telomerase. Cell-culture work shows extended replicative lifespan in human fibroblasts, and rodent work shows lifespan extension.
- Telomerase induction is the mechanism and also the open question. Lengthening telomeres in somatic cells is exactly what a cancer cell does, and nobody has run the long human study that would settle whether that matters here.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Epitalon — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a sceptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a sceptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Evening, through a short course
The pineal and CNS bioregulators are dosed at night because the tissue they target runs on a nocturnal rhythm. For the others the time of day is not the variable that matters — the course-and-gap structure is, and getting that right outweighs any hour of the clock.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
Epitalon reconstitution calculator
Research reconstitution calculator
Where to get Epitalon
Buy Epitalon at AminoWell USA →Epitalon — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Epitalon moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Epitalon — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
Bloodwork to run alongside Epitalon
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | Claimed to modulate the GH axis; this is where that would show |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Inflammation baseline |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 102 markers A–Z
Epitalon — frequently asked questions
What is Epitalon?
Epitalon (Epithalon) is a synthetic pineal-gland tetrapeptide (Ala-Glu-Asp-Gly) from Khavinson's Russian research, studied for telomerase activation, melatonin/sleep support and longevity.
How does Epitalon work?
It's reported to activate telomerase (lengthening telomeres) in cultured cells and to support pineal function and melatonin production, which declines with age. These are its two most-cited mechanisms.
Does Epitalon actually extend lifespan?
Animal studies report increased lifespan, but mostly from the originating research group with limited independent replication, and there are no randomized human lifespan trials. It's promising and mechanistically interesting — not proven in humans.
How is Epitalon dosed?
Khavinson's protocol references 5–10 mg/day by injection for 10–20 days as one 'course,' repeated only 2–3 times a year — a short-intensive-cycle pattern, not daily year-round. Reconstituted with bacteriostatic water (see calculator). Educational, not dosing advice.
Is Epitalon safe?
It's generally reported as well tolerated in the available research, but long-term human safety data is limited, and its telomerase mechanism is something researchers watch. Research-market purity varies. Educational only.
Is Epitalon FDA-approved?
No. Epitalon is not FDA-approved and is sold as a research compound.
References & further reading
- Epithalon: mechanism, effects & research studies (Peptpedia)
- Epithalon research guide — telomerase pathway (Apex)
- Epitalon: complete guide to the pineal tetrapeptide
Want Coach Cam's exact Epitalon protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What Epitalon is used for
Epitalon appears under 4 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.